Clinical Trials
24 trialsNCT06057038 2026-06-02
A Safety Trial of GEN1042 in Japanese Subjects With Malignant Solid Tumors
Genmab
Phase 1 Active not recruiting
NCT06771921 2026-01-30
A First-in-Human Trial of Safety and Efficacy of GEN1078 in Participants With Solid Tumors
Genmab
Phase 1/2 Terminated
NCT06391775 2025-12-26
Trial to Assess the Safety and Preliminary Efficacy of GEN1055 on Malignant Solid Tumors as Monotherapy and as Combination Therapy
Genmab
Phase 1/2 Terminated
NCT06735144 2025-12-05
Phase I/II Clinical Study of FH-006 for Injection in Patients With Malignant Solid Tumors
Jiangsu HengRui Medicine Co., Ltd.
Phase 1/2 Recruiting
NCT05859464 2025-10-20
A Phase 1 Study of ZL-1218 in Subjects With Advanced Solid Tumors
Zai Lab (Hong Kong), Ltd.
Phase 1 Terminated
NCT04632108 2025-09-11
A 1/2 Phase Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antitumor Activity of ASKB589 in Patients With Locally Advanced or Metastatic Solid Tumors
Jiangsu Aosaikang Pharmaceutical Co., Ltd.
Phase 1/2 Active not recruiting
NCT07136142 2025-08-22
A Phase I/II Clinical Study of FH-006 for Injection in Patients With Malignant Solid Tumors
Jiangsu HengRui Medicine Co., Ltd.
Phase 1/2 Not yet recruiting
NCT01309490 2025-07-29
Phase I/II Study of Ribavirin Given as Monotherapy in Solid Tumour Cancer Patients
Jewish General Hospital
Phase 1/2 Terminated
NCT03834662 2024-11-19
A Trial of AVID200, a Transforming Growth Factor β (TGFβ) Inhibitor, in Patients Malignancies
Bristol-Myers Squibb
Phase 1 Completed
NCT03192345 2024-08-07
A First-in-human Study of the Safety, Pharmacokinetics, Pharmacodynamics and Anti-tumor Activity of SAR439459 Monotherapy and Combination of SAR439459 and Cemiplimab in Patients With Advanced Solid Tumors
Sanofi
Phase 1 Completed
NCT03694249 2024-06-27
Ifetroban in Treating Patients With Malignant Solid Tumors at High Risk of Metastatic Recurrence
Vanderbilt-Ingram Cancer Center
Phase 2 Active not recruiting
NCT04571892 2023-04-12
A Clinical Study to Observe the Safety and Efficacy of ScTIL210 in the Treatment of Malignant Solid Tumors
Shanghai East Hospital
Phase 1/2 Unknown
NCT02754141 2023-04-05
An Investigational Immuno-therapy Study of Experimental Medication BMS-986179 Given Alone and in Combination With Nivolumab
Bristol-Myers Squibb
Phase 1/2 Completed
NCT02252211 2022-10-12
LUD2014-002
Ludwig Institute for Cancer Research
Phase 1 Completed
NCT03551795 2022-05-09
Clinical Research on Comprehensive Treatment of Tuberculosis With Malignant Solid Tumor
Shanghai Public Health Clinical Center
Phase 1/2 Completed
NCT01515306 2022-03-08
A Study of Ramucirumab (IMC-1121B) and Paclitaxel in Participants With Solid Tumors
Eli Lilly and Company
Phase 2 Completed
NCT01457118 2021-07-12
An Extension Study of NKTR-102 in Cancer Patients Previously Enrolled in NKTR-102 Studies
Nektar Therapeutics
Phase 2 Completed
NCT03009214 2021-05-10
A Safety and Pharmacokinetic Phase I/Ib Study of AMC303 in Patients With Solid Tumours
amcure GmbH
Phase 1 Completed
NCT00836888 2020-10-08
ONO-4538 Phase I Study in Patients With Advanced Malignant Solid Tumors in Japan
Ono Pharmaceutical Co., Ltd.
Phase 1 Completed
NCT03553108 2020-10-01
IVIVC
AstraZeneca
Phase 1 Completed
NCT04076137 2019-09-03
Targeted T-cell Therapy in Solid Tumors
Benhealth Biopharmaceutical (Shenzhen) Co., Ltd.
Phase EARLY_PHASE1 Unknown
NCT01632696 2017-07-11
Open-label, Single Arm, Tumor Imaging and Dosimetry Study of I-124 PGN650 in Advanced Solid Tumors
Peregrine Pharmaceuticals
Phase EARLY_PHASE1 Terminated
NCT02999750 2016-12-21
EXtendedAnalysis for Cancer Treatment
Medical University of Vienna
Phase NA Unknown
NCT01567163 2014-10-16
A Study of Ramucirumab and Docetaxel in Participants With Solid Tumors
Eli Lilly and Company
Phase 2 Completed